James Java

Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Devansu Tewari, James Java, Ritu Salani et al. · Journal of Clinical Oncology · 2015 · 282 citations · Full text

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

Peter G. Rose, James Java, Charles W. Whitney et al. · Journal of Clinical Oncology · 2015 · 182 citations · Full text

Nodal Metastasis Risk in Endometrioid Endometrial Cancer

Michael R. Milam, James Java, Joan L. Walker et al. · Obstetrics and Gynecology · 2012 · 162 citations · Full text

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Lisa M. Landrum, James Java, Cara Mathews et al. · Gynecologic Oncology · 2013 · 150 citations · Full text

Prognostic Factors, Gynecological Surgery, Intraperitoneal Chemotherapy +8

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study

Krishnansu S. Tewari, James Java, Ramez N. Eskander et al. · Annals of Oncology · 2015 · 125 citations · Full text

Surgical Oncology, Gynecological Surgery, Improved Survival +10